

Review

Open Access

Insights from mouse models into human retinoblastoma

David MacPherson

Address: Department of Embryology, Carnegie Institution, Baltimore, MD, USA

Email: David MacPherson - macpherson@ciwemb.edu

Published: 19 May 2008

Received: 17 April 2008

Cell Division 2008, **3**:9 doi:10.1186/1747-1028-3-9

Accepted: 19 May 2008

This article is available from: <http://www.celldiv.com/content/3/1/9>

© 2008 MacPherson; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Novel murine models of retinoblastoma based on *Rb* gene deletion in concert with inactivation of *Rb* family members have recently been developed. These new *Rb* knockout models of retinoblastoma provide excellent tools for pre-clinical studies and for the exploration of the genetics of tumorigenesis driven by *RB* inactivation. This review focuses on the developmental consequences of *Rb* deletion in the retina and the genetic interactions between *Rb* and the two other members of the pocket protein family, p107 (*Rb1*) and p130 (*Rb2*). There is increasing appreciation that homozygous *RB* mutations are insufficient for human retinoblastoma. Identifying and understanding secondary gene alterations that cooperate with *RB* inactivation in tumorigenesis may be facilitated by mouse models. Recent investigation of the p53 pathway in retinoblastoma, and evidence of spatial topology to early murine retinoblastoma are also discussed in this review.

Introduction

Retinoblastoma is the most common pediatric primary intraocular tumor. Study of retinoblastoma, a malignant cancer that occurs unilateral or a bilateral form, led to the "two-hit hypothesis" now applicable to other inherited cancer syndromes [1]. In bilateral retinoblastoma, an inherited or *de novo* germline mutation in one *RB* allele is typically observed, with such mutations identified in approximately 90% of patients, and the second *RB* allele undergoes somatic mutation [2,3]. In sporadic, unilateral retinoblastoma, somatic mutations occur in both *RB* alleles. The *RB* gene was the first tumor suppressor gene cloned [4], and *RB* is now known to be mutated not only in retinoblastoma but in many cancers, including osteosarcoma, soft tissue sarcoma, small cell lung, breast, brain, prostate, leukemia, and other sporadic cancers [5-9]. Patients with germline *RB* mutation are at increased risk for many of these tumor types and for melanoma [10-12]. They are also at risk for "trilateral retinoblastoma", involving a pediatric midbrain tumor (pinealoblastoma or suprasellar primitive neuroectodermal tumor) in addition

to retinoblastoma [13,14]. Even though *RB* is mutated widely in various human tumor types, the retina is exquisitely sensitive to cancer upon *RB* loss and the reason for this is tissue sensitivity is still poorly understood. Our current knowledge of *RB* function places this gene in pathways central to growth control not only in the retina, but in all tissues. *RB* is a prototypic tumor suppressor gene that encodes pRB, a nuclear phosphoprotein implicated in cell cycle control, differentiation, apoptosis, and many other biological processes. Despite intensive study of this tumor suppressor gene since its cloning, the critical functions of pRB important for tumor suppression are still being unraveled.

Biological functions of the pRB family

pRB is one member of the "pocket proteins", a family that also includes p107 and p130. These proteins are named owing to the presence of a conserved pocket domain, a region that binds E2F transcription factors and various critical protein interactors, many containing an LxCxE motif. The three pocket proteins exhibit similarities, par-

ticularly in the A and B pocket, but there are also clear differences. p107 and p130 have much closer similarity to each other than either to pRB. The pocket proteins differ in their expression patterns, with p107 highly expressed in cycling cells, and p130 expressed at higher levels in cells that have exited the cell cycle [15]. Critical to the function of the pocket proteins are the E2F transcription factors [16]. Pocket proteins can inhibit E2F transactivation activity directly by interfering with the E2F transactivation domain. Also, pocket proteins form complexes with histone deacetylases, histone methyltransferases, histone demethylases, and other chromatin modulators, which act to confer a repressive chromatin state around E2F target genes. There are now 8 known E2Fs, including E2F1 through 8. E2Fs 1–5 act in concert with a DP protein partner to bind the pRB family; pRB binds the so-called activating E2Fs, E2F1, 2, 3a, which have a nuclear localization signal and are strong transcriptional activators. pRB also binds E2F4. p107 and p130 bind E2F4 and 5, often referred to as repressive E2Fs, although p107 and p130 can also form complexes with activating E2Fs under some conditions [17]. E2Fs 6–8 do not function through pocket protein binding. Pocket protein/E2F complexes are dynamic and change upon progression through the cell cycle [18]. The extent to which specific E2Fs mediate pocket protein function and whether E2Fs are the most critical effectors are important questions. The three pocket proteins differ in many binding partners in addition to E2Fs. For example, p130 but not pRB, interacts with members of the DREAM complex, which binds to many promoters and acts to repress cell cycle genes in quiescent cells [19–21]. Notably, this complex includes homologs of *C elegans* SynMuvB genes (important for vulval development) and *Drosophila melanogaster* dREAM (drosophila RBF, E2F and Myb-interacting) complex members. There is also evidence that pRB may bind pro-differentiation factors, such as CBFA1, MITF, C/EPBs and MyoD to promote cell type specific differentiation [22–25]. Data implicating pRB in differentiation control suggest that pRB functions as a positively activating transcriptional co-activator, which is very different from the well-characterized repressive effects of pRB on E2F activity in cell cycle control. The specific effectors for RB family members that contribute to retinoblastoma are not well understood. Here, we focus on insights that study of the murine *Rb* family function in the retina *in vivo* have for understanding human retinoblastoma.

Retinal Development

The neural retina is composed of seven classes of cell types derived from a common population of progenitors, with cell bodies organized into three nuclear layers. The outer nuclear layer contains cell bodies for rod and cone photoreceptors; the inner nuclear layer contains bipolar, amacrine, horizontal and Müller glia cell bodies, and the

ganglion cell layer is made up of ganglion and amacrine cells (Fig 1A). Development of the retina occurs in embryonic and postnatal stages in mice; in humans, retinogenesis is thought to cease near birth [26,27]. The retina derives from anterior tube neuroepithelium that undergoes a lateral bulge after neural tube closure, forming the optic vesicle (reviewed in [28]). Invagination of the central part of the optic vesicle leads to formation of a bilayered optic cup, with an inner layer that forms neural retina, and an outer layer that forms the retinal pigment epithelium. Progenitor cells undergo mitosis along the outer edge of the retina in the retinal ventricular zone. Interkinetic migration occurs such that nuclei migrate away from this zone to undergo G1, S and G2 cycle stages and return for the next mitosis [27]. Lineage tracing studies using retroviral vectors have revealed that mature retinal cell types derive from multipotent progenitors. Potency differs as development proceeds, such that embryonic mitotic clones can contain almost all possible cell types, while postnatal clones are more restricted [29,30]. However, even at late postnatal stages in rodents, 2-cell clones can contain both a Müller glia cell and a rod photoreceptor illustrating multipotency even up until the last cell division [30]. Following cell cycle exit, cells differentiate, migrate to the correct layer and establish appropriate synaptic connections. The developing retina is a simple and very well characterized region of the central nervous system with a defined order of cell type generation, markers for each cell type, and spatial localization of cells at different stages of the cell cycle. Also, the retina is accessible to manipulation *in vivo* using plasmid electroporation, or, if stable expression over many cell divisions is needed, viral vectors. These properties make the retina an ideal system to study not only development, but also cancer initiation. For childhood cancers these processes are clearly intertwined.

Human retinoblastoma

Retinoblastoma is a pediatric cancer that is typically detected in the first few years of life but can arise during embryonic retinal development [31]. The identity of the specific cell from which retinoblastoma arises is unknown. It has been proposed that retinoblastoma arises from a primitive neuroectodermal cell with multipotent potential [32]. Histologically, retinoblastomas exhibit neuronal differentiation and exhibit focal regions that contain rosettes. Homer-Wright rosettes, indicative of neuroblastic differentiation are present in retinoblastoma and various neuroectodermal tumors (Fig 1b). Flexner-Wintersteiner rosettes exhibit ultrastructural evidence of photoreceptor differentiation [33,34]. Primitive outer segments in such rosettes stain positively for markers of photoreceptor antigens such as interphotoreceptor binding protein (IRBP) and opsins (See Fig. 1c). The rod photoreceptor rhodopsin was found in Flexner-Wintersteiner

rosettes in most tumors examined [35,36] and, in a separate study, both rod and cone markers were expressed in many retinoblastomas, with increased staining of cone markers over rod markers [37]. The stronger cone character of retinoblastoma is also supported by studies of a number of cell lines, which revealed mRNA for cone but not rod cGMP phosphodiesterase, and cone transducins [38,39]. Together, these observations have led to a view that retinoblastoma is derived from a developing photoreceptor or a cell with the potential to adopt a photoreceptor cell fate. The question of whether the retinoblastoma-originating cell is a post-mitotic cell specified to become a photoreceptor (i.e. a transition cell), or a restricted progenitor, or a broadly multipotent cell capable of forming many cell types must be resolved.

Lineage tracing studies in the normal rodent retina do not support the existence of specific progenitors that generate only rod and cone photoreceptors [30]. Instead, such studies have revealed that normal retinal progenitor cells are multipotent; clones containing cones, an early born cell type, almost always included different cell types as well [29]. If retinoblastoma is derived from a progenitor cell capable of forming cone photoreceptors, then such a cell would be expected to have broad potency. While much of the focus of retinoblastoma cell of origin studies has been on photoreceptors, inner cell layer markers have also been detected in retinoblastoma [40]. Also, early retinoblastomas sometimes appear to emerge from the inner nuclear layer and not the photoreceptor layer implicating a possible inner layer cell-of-origin [41]. There are many reports describing Müller cells in retinoblastoma [42,43], but it has been debated whether such cells are neoplastic, as opposed to reactive non-tumor cells [44]. Findings that retinoblastoma cells in culture can be induced to express glial markers and exhibit the potential to differentiate into neuron or glial cells support the idea that retinoblastomas arise from multipotent progenitor cells [32]; however, direct evidence of neoplasia in Müller cells from retinoblastoma cells that have not undergone long term culture is needed. Observations that normal progenitor cells in rodents can generate clones containing rods, cones, Müller glia and other cells [29] support the idea that cell type heterogeneity in retinoblastoma may be due to transformation of a progenitor that is normally multipotent, but dedifferentiation or trans-differentiation of a cell-type specified cell-of-origin cannot be ruled out. More recently, stem cell markers have been found expressed in human retinoblastoma cell lines, such as Oct3/4 and Nestin [45,46]. Overall, the human data suggest tumor origin in a multipotent cell but the extent to which these cells are multipotent requires further examination.

There are limitations to using human tumor samples to identify the tumor cell of origin. In the establishment and long term passaging of cell lines, genetic alterations may occur that alter the cell's properties. Also, accessing early retinoblastomas is rarely possible, limiting analysis to late stage tumors that may have quite different characteristics compared to the earliest lesions. Use of model systems can help in assessing the early events in tumorigenesis.

Transgenic retinoblastoma models

A number of models of retinoblastoma have been developed that have made use of transgenic expression of specific viral oncoproteins. The most widely used such model, the *LH-beta T-Ag* model expresses the SV40 early region under control of the Luteinizing hormone beta promoter [47]. The development of retinoblastomas in one *LH-beta T-Ag* line was in part a consequence of the genomic site of integration directing transgene expression to cells in the retina, a tissue in which luteinizing hormone beta is not normally expressed. Both Large-T and small-t oncoproteins are encoded by the SV40 early region and may contribute to tumorigenesis. Large-T Ag binds the pRB family, p53, and other proteins, such as CBP/p300. Small-t Ag also contributes to transformation in cell culture, in part through binding the phosphatase pp2A [48]. In the *LH-beta T-Ag* model, retinoblastoma with neuronal characteristics and histological similarities to human retinoblastomas emerged. Transgenic mice expressing T-Ag/t-Ag from the *IRBP* promoter have also been generated and develop retinoblastoma [49-51]. *IRBP* is expressed not only in photoreceptor cells but in some progenitor cells [52], raising the possibility of a progenitor or newly post-mitotic cell of origin. Also, Phenylethanolamine N-methyltransferase-driven T-Ag (*PNMT-T-Ag*) transgenic mice develop retinal tumors that arise at the retina periphery. This spatial localization of retinal tumors in mice occurred despite T-Ag/t-Ag being expressed in amacrine and horizontal cells in both central and peripheral retina [53,54]. The authors suggest that the tumors arise from amacrine or horizontal cells [54] but it is not clear why the tumors were peripheral as these cell types are present throughout the retina.

Papillomavirus E7 protein binds to the pocket protein family, and other effectors, but does not inactivate p53. *IRBP-E7* mice underwent photoreceptor degeneration, while *IRBP-E7; p53^{-/-}* animals were prone to tumors of the retina that arise in the photoreceptor layer [55]. While initially, it was proposed that *p53* loss suppressed E7-dependent apoptosis, leading to retinoblastoma, *p53* loss may contribute in other ways, as these tumors are now recognized to emerge in the midst of high levels of apoptosis and photoreceptor degeneration even upon *p53* deficiency [56]. This distinction is important, as in other mouse models, there is good evidence that functions of

p53 independent of apoptosis are critical for tumor suppressor ability [57]. This is also relevant to a renewed interest in the role of *p53* in retinoblastoma discussed further on in this review. Whether the tumors in the *IRBP-E7;p53-/-*, *LH-beta T-Ag* and *PNMT-Tag* models exhibit a similar cell of origin or if these models represent distinct tumors of different cell types remains to be determined.

Use of transgenic retinoblastoma models has been valuable for the testing of preclinical therapeutics; however, the development of models that target *Rb* but not other effectors of viral oncoproteins has been a clear goal for improvement of mouse retinoblastoma models. The main disadvantage of transgenic models expressing viral oncoproteins concerns the pleiotropic effects of the oncoproteins, which impact upon multiple signaling pathways. These oncoproteins may also have important targets not yet identified. Furthermore, tumors in which *p53* is functionally ablated through T-Ag expression are not ideal for testing therapies, whose effectiveness may depend on the *p53* pathway being intact [58,59].

"Rb knockout" models of retinoblastoma

The generation of mouse models that, like human retinoblastoma, exhibit *Rb* deletion took a number of years. Three groups inactivated *Rb* in the mouse germline, resulting in embryonic lethality in *Rb-/-* animals and the development of pituitary and thyroid tumors in *Rb+/-* animals [60-62]. Retinoblastomas never occurred in the murine *Rb* heterozygotes, in stark contrast to the high retinoblastoma incidence in humans with germline *RB* mutation. The Jacks and the Berns groups both generated chimeric animals in which *Rb-/-* cells contributed to the retina, but retinoblastomas still did not form [63,64]. With the generation of chimeric animals lacking *Rb* and *p107* came the

realization that mice were capable of developing retinoblastoma dependent on *Rb* deletion [65]. However, the study of large numbers of retinoblastoma-bearing animals was not practical using this chimera model. Indeed, the low recovery of viable chimeras suggested significant developmental lethality upon high contribution of *Rb-/-*; *p107-/-* cells to the developing embryo.

Nevertheless, the advent of *Cre-lox* technology and *Cre*-expressing transgenic animals with expression in the developing retina paved the way for the generation of breedable *Rb*-knockout models of retinoblastoma. The first attempt, based upon the previous descriptions of photoreceptor characteristics in retinoblastoma used *Cre* regulated by the *IRBP* promoter together with *Rb^{Lox}* alleles to drive *Rb* deletion in the photoreceptor compartment and in other tissues [66]. These mice did not develop retinoblastoma, even when combined with both *p107* and *p53* deficiency, indicating that the tumor-initiating cells in *Rb/p107* DKO chimeras were not being targeted when these genes were deleted in developing photoreceptors. Breedable *Rb*-knockout models of retinoblastoma were independently generated using *Cre* transgenics with expression driven by *Nestin*, *Chx10* and *Pax-6* promoter in progenitor and other cells [67-70]. New retinoblastoma models confirmed the tumor suppressor function of *p107* first revealed in chimera studies. Mouse models have now revealed that inactivation of the third pocket protein, *p130*, also cooperates very strongly with *Rb* deletion to promote retinoblastomas in both *Rb* knockout and chimeric mice [68,69,71]. A summary of the different *Rb*-knockout and chimeric retinoblastoma models is provided in Table 1. The breedable *Rb* knockout models of retinoblastoma now provide excellent tools to hone in on

Table 1: *Rb-/-* mouse models of retinoblastoma

Model	Frequency	Tumor Characteristics	References
<i>Rb-/-p107-/-</i> chimeras	5/7 mice (1/5 bilateral)	Positive staining for amacrine markers, some Müller cells present	[65]
<i>Rb-/-p130-/-</i> chimeras	5/11 mice (2/5 bilateral)	Positive staining for amacrine markers, some Müller cells present	[71]
α - <i>Cre</i> ; <i>Rb^{lox/lox}</i> ; <i>p107-/-</i>	> 60%	Positive staining for amacrine markers, some Müller cells present	[67, 68]
α - <i>Cre</i> ; <i>Rb^{lox/lox}</i> ; <i>p130-/-</i>	29/29 mice (bilateral)	Average 280 days to externally visible retinoblastoma	
		Positive staining for amacrine and horizontal markers, some Müller cells present	[68]
		Average 128 days to externally visible retinoblastoma	
		Lymph node and brain metastasis	
<i>NesCre1</i> ; <i>Rb^{lox/lox}</i> ; <i>p130-/-</i>	5/5 mice (4/5 bilateral)	Positive staining for amacrine markers, some Müller cells present	[69]
<i>Chx10Cre</i> ; <i>Rb^{lox/lox}</i> ; <i>p107-/-</i>	~60%	Positive staining for amacrine, horizontal and progenitor markers	[89]
<i>Chx10Cre</i> ; <i>Rb^{lox/lox}</i> ; <i>p107-/-</i> ; <i>p53-/-</i>	100% (bilateral)	Positive staining for amacrine, horizontal and progenitor markers	[70, 89, 129]
		Increase in less differentiated cells vs. <i>Chx10Cre</i> ; <i>Rb^{lox/lox}</i> <i>p107-/-</i> tumors	
		Average 100 days before mice were moribund	
<i>Chx10Cre</i> ; <i>Rb^{lox/lox}</i> ; <i>p130-/-</i> ; <i>p107+/-</i>	45/45 mice (bilateral)	Positive staining for horizontal cell markers in primary tumors	[95]
		Metastases did not stain for horizontal cell markers	
		Tumors arose at 8-14 weeks	

the cell of origin and interrogate the molecular genetics of retinoblastoma progression.

Rb in murine retinal development

Retinoblastoma is a clear example of a tumor with developmental origins and, as such, its understanding requires knowledge of the normal developmental role of *Rb* in the retina. Homozygous germline *Rb* deletion in mice leads to embryonic lethality in midgestation, caused by placental deficiency [60-62,72]. *Rb* has been inactivated in the retina using a number of different systems that bypass the lethality associated with systemic *Rb* deletion. *Rb*^{-/+} chimeric animals and various *Cre*-expressing transgenics, including *Chx10-cre*, *Pax6* α -enhancer *Cre* (α -*Cre*) and *NesCre1*, in concert with an *Rb lox/lox* allele exhibit *Rb* deletion in the retina [67,69,73]. These models inactivate *Rb* at different times and in different cells. *Chx10-Cre* is expressed in a mosaic pattern in progenitor cells, and in adults is expressed in most bipolar cells and in some Müller cells [73]. *NesCre1* is active in the optic vesicle by E9.5 and exhibits different expression upon paternal vs. maternal inheritance of the transgene [69]. Complete recombination in the retina occurs upon paternal *Cre* transmission and is accompanied by lethality at birth in *Rb^{lox/lox}* animals. A mosaic pattern of *Cre* expression is observed with maternal *NesCre1* inheritance allowing for the survival of some animals on an *Rb^{lox/lox}* background. α -*Cre* is expressed by E10.5 in distal progenitor cells, with a dorsal gap in expression [74]. In addition to the widespread expression in peripheral progenitors, certain cells in the inner nuclear layer and ganglion cell layer express α -*Cre* at late stages both in central and peripheral retina. A synthesis of the data from many groups using different systems has revealed common phenotypes that have implicated *Rb* in control of proliferation, apoptosis and differentiation in the developing retina (Table 2).

In embryonic stages of retinal development, the first indication that there were cell cycle defects upon *Rb* deletion came from *Rb*^{-/+};*Rb*^{+/+} chimeric animals in which mitotic figures and high levels of cell death were found in the inner retina from E16.5 to E18.5 [63]. Ectopic proliferation in the retinal ganglion cell layer has been observed as early as E13.5 in germline *Rb* mutants [75]. Ectopic proliferation coupled to apoptosis in the inner embryonic *Rb*^{-/-} retina was also observed in α -*Cre* and *Nes-Cre1* mice [67,69]. Normal retinal mitoses are restricted to the outer edge of the retina and never occur in the differentiating inner region suggesting that differentiating *Rb*^{-/-} cells exhibit defects in exiting the cell cycle. The most pronounced effects of *Rb* deletion are seen in late stages of retinal development, as *Rb* loss causes the proliferative period of retinogenesis to be extended [67-69]. Notably, the inappropriately proliferating *Rb*^{-/-} cells at early and late developmental stages express markers associated with

differentiation of each of the seven classes of retinal cell types, leading to the idea that *Rb* deletion primarily causes normally post-mitotic, cell-type specified cells (termed transition cells, or precursor cells) to proliferate inappropriately [67]. However, differentiation markers may also be expressed in cells that have not yet committed to a certain cell fate, and it is possible that both progenitor cells and transition cells are affected by *Rb* loss [76]. Importantly, cells in the *Rb*-deficient retina ultimately exited the cell cycle or died such that by PND21, *Rb*^{-/-} cells no longer proliferate, and retinoblastoma never develops [67,68]. Interestingly, the high level of apoptosis that occurs upon *Rb* deletion differentially affects specific cell types. Bipolar cells, ganglion cells as well as the majority of rod photoreceptors are lost in α -*Cre Rb^{lox/lox}* mice. Photoreceptor apoptosis is specific to rods, as cells expressing cone markers were present in normal numbers, revealing specificity to rod cell death [67]. The cell death data are consistent with results from *Rb*^{-/+};*Rb*^{+/+} chimeras, in which there was a low, but not null, contribution of *Rb*^{-/-} cells to the adult retina [63].

Finally, *Rb* loss has been associated with differentiation defects. Rod photoreceptors in *Chx10Cre Rb^{lox/lox}* mice have been reported to exhibit an altered pattern of heterochromatin suggestive of rod maturation defects [73,77,78]. It has been argued that differentiation defects represent direct effects of *Rb* loss, but it is difficult to distinguish between downstream effects of *Rb* loss on cell cycle control vs. direct effects on differentiation. Interestingly, defects in rod development were not found when *IRBP-Cre* was used to drive *Rb* deletion in photoreceptor transition cells [66]. One explanation is that rod differentiation requires pRB only at a progenitor stage prior to IRBP expression but not at later stages. It will be important to precisely determine the specific stage in rod development that is affected. Expression of genes associated with rod synaptogenesis were not altered in *Rb*^{-/-} explant cultures or in *Chx10Cre Rb^{lox/lox}* retinas [78], suggesting that the rods are not completely blocked at a progenitor stage. Nevertheless, some cells express progenitor cell markers in the outer nuclear layer in *Chx10Cre Rb^{lox/lox}* animals [77]; these may be undifferentiated rods, but the possibility that cells other than photoreceptor cells may have inappropriately migrated to the outer nuclear layer complicates their identification. *NesCre1*, *Chx10Cre* and α -*Cre Rb^{lox/lox}* mice all exhibit the presence of ectopic cells in the outer plexiform layer that extend to the photoreceptor layer [69,78], and the origin of these cells has not been determined. Other differentiation defects in *Rb*-mutant retinas have also been noted. *Rb*-deficient starburst amacrine cells were found to lack the expression of markers associated with their maturation [79]. Also, a subset of *Rb*-deficient horizontal cells exhibit enlarged abnormally shaped nuclei, reminiscent of polyploid cells that have

undergone endoreduplication in other *Rb*-deficient cell types, such as skeletal muscle and Purkinje cells [64,69]. Defects in *Rb*-deficient horizontal cells involving ectopic processes that extend into the outer nuclear layer have also been described [77].

While there are many similarities between the phenotypes observed following *Rb* deletion using chimera systems and different *Cre*-transgenic lines (Table 2), some differences have also been found. Overall, milder proliferative and apoptotic phenotypes have been reported in studies using *Chx10Cre*-mediated *Rb* deletion versus other systems to inactivate *Rb* in the retina (Table 2). For example, while bipolar cells undergo cell death in α *Cre* *Rb*^{lox/lox} retinas [67,69], this phenotype has not been observed in *Chx10Cre* *Rb*^{lox/lox} retinas [78]. Differences in genetic background across different strains could contribute to differing phenotypes. It is also possible that differences in the timing of *Cre* expression across various cell types may underlie the differing phenotypes observed. Endogenous retinal *Chx10*, like *Chx10Cre*, is expressed not only in progenitor cells, but, later in retinal development, in mature inner nuclear cells including bipolar cells [73,80]. If heterogeneity in the timing of *Rb* deletion across different cells occurs in animals exhibiting a mosaic pattern of *Cre* expression, different phenotypes may result. Whether *Rb*

is required to maintain cell cycle exit, cell survival and/or differentiation characteristics when deleted late in retinal development is not known and will be important to determine. A second possibility is that in regions of extensive *Rb* deletion, non-cell-autonomous effects contribute to the death of rod, bipolar and ganglion cells. To determine if effects of *Rb* deletion are cell autonomous, the ideal experiment involves stably marking the daughters of mitotic cells using replication-deficient retroviral vectors [81]. Lineage tracing experiments using a retrovirus to express *Cre* recombinase in newborn animals followed by analysis of clone composition have suggested that defects in rod photoreceptors are cell autonomous [73]. In the same study, while 12 of 115 control clones in *Rb*_{lox/+} animals contained bipolar cells following *Cre* expression, 0 of 82 clones in *Rb*_{lox/-} animals contained bipolar cells (data from Supplemental Table 2 in [73]). A similar lack of bipolar-containing clones was observed upon functional pRB inactivation through expression of E1A. While larger studies are needed, these numbers suggest that apoptosis is also at least partially cell autonomous in *Rb*^{-/-} bipolar cells. Finally, milder phenotypes may simply be more difficult to detect in animals with a low level of mosaic *Rb* deletion. That is, detecting phenotypes associated with the rapid apoptosis of certain cell types may be facilitated when there is widespread deletion as in *NesCre1* *Rb*^{lox/lox}

Table 2: Developmental phenotypes upon *Rb* deletion in the retina

Genotype	Major Developmental Phenotypes	References
<i>Rb</i> ^{-/-} chimera	Apoptosis and ectopic mitosis at E16.5–E18.5 in inner layer Loss of most <i>Rb</i> ^{-/-} cells from all retinal layers in adults	[63]
<i>Rb</i> ^{-/-} <i>p107</i> ^{-/-} chimera	Apoptosis and retinal dysplasia at E17.5 Photoreceptor death by PND15	[65]
<i>Rb</i> ^{-/-} <i>p130</i> ^{-/-} chimera	Inner layer proliferation at PND14	[71]
<i>NesCre1</i> ; <i>Rb</i> ^{lox/lox}	Inner cell layer apoptosis and ectopic BrdU at E18.5 Photoreceptor degeneration in adult mosaic animals	[69]
<i>NesCre1</i> ; <i>Rb</i> ^{lox/lox} ; <i>p53</i> ^{-/-}	Inner cell layer apoptosis and ectopic BrdU at E18.5 Photoreceptor layer degeneration in adult mosaic animals	[69]
<i>Chx10Cre</i> ; <i>Rb</i> ^{lox/lox}	Defective rod differentiation and rod cell death Ectopic cells in outer plexiform layer	[73, 77, 78]
<i>Chx10Cre</i> ; <i>Rb</i> ^{lox/lox} ; <i>p107</i> ^{-/-}	Increased proliferation of cells expressing progenitor and amacrine markers at PND30	[84]
α <i>Cre</i> ; <i>Rb</i> ^{lox/lox}	Increased apoptosis and proliferation in embryonic inner retina Extension of normal proliferative period of retinal development Ectopic proliferation of transition cells expressing markers of all 7 cell types Death of most bipolar cells, ganglion cells and a subset of rods Defective starburst amacrine cell differentiation	[67-69, 79]
α <i>Cre</i> ; <i>Rb</i> ^{lox/lox} ; <i>p107</i> ^{-/-}	Increased apoptosis and proliferation over <i>Rb</i> mutants Death of all peripheral cells except amacrine, horizontal and Müller cells	[67]
α <i>Cre</i> ; <i>Rb</i> ^{lox/lox} ; <i>p130</i> ^{-/-}	Increased proliferation and apoptosis over <i>Rb</i> mutants Severe degeneration from PND21 to PND31 Hyperplasia at extreme periphery in all mice by PND31	[68]
α <i>Cre</i> ; <i>Rb</i> ^{lox/lox} ; <i>E2f1</i> ^{-/-}	Rescue of inappropriate proliferation and apoptosis in bipolar, ganglion cells and rods Rescue of electroretinogram response Defects in starburst amacrine cell differentiation remain	[79]
α <i>Cre</i> ; <i>Rb</i> ^{lox/lox} ; <i>E2f2</i> ^{-/-}	Phenotype similar to <i>Pax6</i> α <i>Cre</i> <i>Rb</i> ^{lox/lox} retinas	[79]
α <i>Cre</i> <i>Rb</i> ^{lox/lox} ; <i>E2f3</i> ^{-/-} (or <i>E2f3a</i> ^{-/-})	No rescue of cell death or ectopic cell division Rescue of starburst amacrine cell differentiation	[79]

retinas, or in the mid-far periphery of α -Cre $Rb^{lox/lox}$ retinas.

The phenotypes upon Rb loss are quite similar across studies of chimeras, α -Cre and $NesCre1$ mice, with milder phenotypes observed upon $Chx10Cre$ -mediated Rb inactivation. Differences highlight the need to assess the consequences of Rb deletion at different times across different cell types, and the need to better understand the extent to which phenotypes are cell autonomous. Some of these aims may be achieved by expressing Cre in a temporally and dosage controllable fashion using either viral delivery or tamoxifen-inducible $Cre-ER$ transgenics with $Cre-ER$ expression driven by cell-type specific promoters.

Effectors of Rb in the retina

The importance of specific $E2f$ family members in mediating Rb dependent phenotypes is of great debate. Analyses of $E2f$ contribution to Rb -mutant developmental phenotypes have been performed in the whole animal through compound mutant studies, but the non-cell autonomous consequences of placental dysfunction in $Rb^{-/-}$ embryos complicate the interpretation of these results. Compound mutant analysis specifically in the developing retina provides an excellent system to probe these interactions. The importance of $E2f1$ in mediating the effects of Rb loss was nicely shown by the Bremner group as compound mutation of Rb and $E2f1$ rescued much of the proliferation and apoptosis associated with Rb deletion using the α -Cre $Rb^{lox/lox}$ system, and even restored response on the electroretinogram, a measure of retinal electrical activity in response to light [79]. Interestingly, these authors showed that $E2f1$ loss did not rescue differentiation defects in Rb -deficient starburst amacrine cells. In contrast, compound mutation of Rb and $E2F3a$ led to a rescue in starburst amacrine cell development suggesting that $Rb/E2F3a$ interactions promote the differentiation of these cells. While pro-differentiation effects of pRB are often thought $E2f$ -independent, this is one example of pRB promoting the differentiation of a cell type mediated through $E2F$.

It will be critical to dissect the pathway between Rb loss and apoptosis in the developing retina. The above study showed that apoptosis is $E2f$ -dependent, but the $E2f$ effectors that contribute to apoptosis remain to be identified. We were interested in whether $p53$ was downstream of Rb inactivation in the retina [69]. Compound $NesCre1 Rb^{lox/lox} p53^{-/-}$ double mutants did not exhibit rescue of apoptosis in the embryonic retinal ganglion cell layer. Also, the loss of photoreceptors was not rescued in $NesCre1 Rb^{lox/lox} p53^{-/-}$ animals exhibiting deletion of Rb in a mosaic pattern. Rb loss has been linked to apoptosis as pRB is an anti-apoptotic protein and many $E2F$ target genes are apoptosis effectors [82]. Whether or not it is important to suppress apoptosis for retinoblastoma development is a

point of contention, but in many human cancers, tumors may not form unless an apoptotic pathway that is activated following Rb deletion is abrogated [83]. Elucidation of the effectors of the $p53$ -independent apoptosis downstream of Rb loss in the retina will be an important goal for broadly understanding the events that synergize with Rb loss to promote cancer.

Functional overlap among the pocket proteins

Data from chimeras and conditional mutants exhibiting inactivation of Rb as well as $p107$ or $p130$ loss clearly illustrate tumor suppressive activity of $p107$ or $p130$ in the context of Rb deficiency. It is not clear why retinoblastoma manifests itself in mice only if $p107$ or $p130$ is inactivated in addition to pRB. $p107$ expression is upregulated in murine retinas lacking Rb but not in human retina explants with knockdown of RB expression, raising the possibility that $p107$ upregulation prevents retinoblastoma in mice. [84]. However, increased expression of $p107$ in $Rb^{-/-}$ murine retinal cells has been reported only at postnatal stages of retinal development, or in explant cultures differentiated *in vitro* to recapitulate postnatal stages of retinal development and not in embryonic $Rb^{-/-}$ retina [69,84]. Importantly, an increase in proliferation occurs in $Rb^{-/-}$ retinas at late time points in retinal development [67-69]. As $p107$ is an $E2f$ target gene typically expressed in proliferating but not post-mitotic cells, the $p107$ increase has not been uncoupled from the cell cycle phenotypes associated with Rb loss at late stages in retinal development. Other Rb targets, such as Cyclin E are found strongly upregulated at both embryonic and postnatal stages of retinal development in Rb -deficient retinas (D.M. unpublished). It is also possible that functional overlap among the pocket proteins without increased $p107$ or $p130$ expression is critical for suppressing retinoblastoma in mice. Indeed, $p130$ is a stronger suppressor of retinoblastoma than $p107$ despite no alterations in $p130$ overall levels upon Rb loss [68,69]. Factors that regulate pocket protein activity may differ in their levels or activity in mice compared to humans (either in the normal situation, or in response to Rb loss) and many upstream regulators of pocket proteins are known to be important for cell cycle control in the retina. $Cyclin D1^{-/-}$ retinas are hypoplastic, corresponding to altered pocket protein phosphorylation [85]. High cyclin D1 levels likely promote normal progenitor cell expansion by keeping the pocket proteins inactive. A decrease in the level of murine cyclin D1 occurs in response to Rb family inactivation and this decrease may contribute to retinoblastoma suppression in mice through regulation of pocket protein activity [69]. Indeed, there is a good correlation between the level of cyclin D1 and the extent of $p107$ phosphorylation in retinas lacking Rb or both Rb and $p130$ compared to controls. $p27^{-/-}$ retinas exhibit an extension in the period of retinogenesis, implicating $p27$ in cell cycle exit in a subset of cells [86].

p19(*Ink4d*) loss also extends the normal period of retinal proliferation in the retina [87]. Whether upstream regulators of p107 and p130 activity such as cyclin D1, p27 and p19Ink4d can contribute to retinoblastoma in the context of p107 or p130 being intact will be important to elucidate. It is likely that complex differences between mice and humans in the levels and activity of multiple regulators of the RB family contributes to the species difference in retinoblastoma susceptibility. Thus, a broader understanding of the regulation of pRB, p107 and p130 in the cell from which retinoblastoma is derived is needed.

Genetic interactions between Rb and p107 in the retina

Many of the developmental phenotypes associated with retinal *Rb* loss are exacerbated upon additional mutation of p107, revealing the functional overlap among these family members [65,67,69]. Embryonic retinal proliferation and apoptosis are increased upon both *Rb* and p107 mutation. While rod and some cone photoreceptors survive when *Rb* is deleted in progenitor cells using the α -*Cre* model, almost all are lost upon additional mutation of p107 [67]. Nevertheless, many amacrine cells, horizontal cells and Müller cells survived *Rb* and p107 deletion and a subset of such animals developed retinoblastoma. Tumor emergence from highly apoptotic retinas suggests that the cell of origin of retinoblastoma in this model exhibits intrinsic resistance to apoptosis. However, death resistance is a relative term; despite the cell of origin surviving *Rb/p107* loss, emerging retinoblastomas can be highly apoptotic [68] similar to human retinoblastomas. Secondary alterations that confer evasion of apoptosis may indeed contribute to the progression of retinoblastoma, but this does not diminish the importance of the tumor cell of origin surviving when only three cell types survived in α -*Cre Rb/p107* DKO mice [67]. Retinoblastomas from *Rb/p107* chimeras or α -*Cre Rb^{lox/lox} p107^{-/-}* mice exhibited positive immunostaining for multiple amacrine markers. Amacrine cells are a heterogeneous population with one estimate of 29 subtypes [88]. Heterogeneity in the expression of specific amacrine markers within a tumor and between different tumors suggests that the tumors arise from a cell capable of forming multiple amacrine subtypes. Also, horizontal cells may also be present [89] and some cells expressing glial cell markers [65,67,68] have been observed in retinoblastomas lacking *Rb* and p107. Together, these data raise the possibility that tumor cell of origin is capable of generating multiple cell types.

Long latency of tumorigenesis and incomplete penetrance suggests that *Rb* and p107 inactivation is not sufficient for retinoblastoma. Thus, the *Rb/p107* DKO models are ideal for testing genes that potentially cooperate with loss of *Rb* in retinoblastoma development, and to probe the nature of the block(s) that must be overcome.

Genetic interactions between Rb and p130 in the retina

Interactions between *Rb* and p130 in the retina have revealed roles for p130 in tumor suppression and retinal development in α -*Cre Rb^{lox/lox} p130^{-/-}*, *NesCre1 Rb^{lox/lox} p130^{-/-}* and in *Rb^{-/-}p130^{-/-}* chimeras [68,69,71]. In contrast to the embryonic disorganization in *NesCre1 Rb/p107* DKO retinas, histological defects were not found in *NesCre1 Rb/p130* DKO embryonic retinas [69]. In postnatal stages of retinal development, proliferation defects are exacerbated by p12 in α -*Cre Rb/p130* DKO mice, relative to α -*Cre Rb^{lox/lox}* single mutants, revealing cooperation between *Rb* and p130 in controlling cell cycle exit in late stages of retinal development. By PND21, *Rb^{-/-}* cells have all exited the cell cycle, but cells in α -*Cre Rb^{lox/lox} p130^{-/-}* retinas continue to inappropriately undergo S-phase entry and exhibit the presence of cells with large aberrant nuclei [68]. Proliferative phenotypes are coupled to high levels of cell death, with severe degeneration in the α -*Cre Rb^{lox/lox} p130^{-/-}* retina. The extent to which this cell death is cell autonomous has not yet been determined and it is possible that effects of *Rb* and p130 loss on certain cell types may lead to the death of other cells through secondary effects. Cell death is more pronounced in these animals than α -*Cre Rb^{lox/lox} p107^{-/-}* retinas, although some cells, including horizontal cells, Müller cells and rare amacrine cells survive at PND21. The survival and increase in horizontal cells at this stage is a specific effect of *Rb* and p130 loss not observed upon *Rb* and p107 deletion.

Chimeric animals lacking *Rb* and p130, *NesCre1 Rb^{lox/lox} p130^{-/-}* and α -*Cre Rb^{lox/lox} p130^{-/-}* mice all develop retinoblastomas in which marker expression is heterogeneous and includes the expression of amacrine markers [68,69,71]. Regions of horizontal cell differentiation are also found in α -*Cre Rb^{lox/lox} p130^{-/-}* and *NesCre1 Rb^{lox/lox} p130^{-/-}* retinoblastomas ([68] and D.M. unpublished). *Rb/p130* DKO retinoblastomas appear similar to *Rb/p107* DKO retinoblastomas upon histological examination, and both resemble human retinoblastomas with neuroblastic differentiation (See Figure 1). Early lesions resembling retinoblastoma, with Homer-Wright rosettes, were observed by PND21 to PND31 in α -*Cre Rb^{lox/lox} p130^{-/-}* animals at the extreme periphery of the retina [68]. Our observation of peripheral early lesions in α -*Cre Rb^{lox/lox} p107^{-/-}* animals points to a possible niche for the cell of origin in both models. This may be similar to the localization of tumors from *PNMT-Tag* animals [53,54] and there are also indications that early retinoblastomas in the *LH-beta T-Ag* model preferentially locate to the retina periphery [90,91]. Notably, despite the death of most amacrine cells away from early tumors at PND21, tumorigenesis is actually more prevalent in the α -*Cre Rb/p130* DKO model than the α -*Cre Rb/p107* DKO model, suggesting that the tumors may not derive from amacrine cells or that only a specific subset of peripheral amacrine cells are sensitive to tumor-




Figure 1
Normal retina and retinoblastoma (A) Thin section of normal murine retina with outer nuclear (ONL), inner nuclear layer (INL) and ganglion cell layer (GCL) shown. **(B)** Hematoxylin and Eosin (H+E) stain of human retinoblastoma with neuroblastic differentiation and Homer-Wright (HW) rosettes. **(C)** H+E staining of human retinoblastoma exhibiting Flexner-Wintersteiner (FW) rosettes. Inset: M-opsin immunostaining showing evidence of cone differentiation. **(D)** H+E of primary murine retinoblastoma lacking *Rb* and *p130* with Homer-Wright rosettes indicated.

genesis. [68]. Peripheral progenitor cells/stem cells, Müller glia and horizontal cells are all alternative candidates. Complete retinoblastoma penetrance is striking given the high cell death and suggests that the cell of origin of *Rb/p130* DKO tumors is less sensitive to apoptosis than most cells in the retina.

Rb/p130 DKO retinoblastomas proceed to fill the vitreous, and a subset invade the optic nerve and undergo tumor extension into the brain, similar to advanced human retinoblastoma. Tumors also metastasize to cervical lymph nodes. The α -*Cre Rb/p130* DKO model is a better model for advanced retinoblastoma given the rapid tumor kinetics. The importance of a mouse model of metastatic retinoblastoma is evident from the poor prognosis of humans with retinoblastoma metastasis [92,93]. In developed countries, retinoblastoma is well treated, with about 4% mortality, however, even with the best care, retinoblastoma with CNS involvement exhibits extremely high mortality [94]. The majority of children with retinoblastoma are born in less developed countries, where delayed retinoblastoma diagnosis leads to extraocular disease; in some parts of the world this results in mortality as high as

90% [94]. Better tumor-eradicating treatments are clearly needed. The advanced tumor progression and the rapid, consistent kinetics in the α -*Cre Rb^{lox/lox} p130^{-/-}* animals make this an excellent model for preclinical testing of novel therapies for early and advanced retinoblastoma.

Effects of *p107* vs. *p130* loss in concert with *Rb* in the retina

The differences between *Rb/p107* DKO and *Rb/p130* DKO models confirm that *p107* and *p130* have differing functions. Distinct cell-type specific effects occur upon *Rb* and *p107* vs. *Rb* and *p130* inactivation in the developing retina. Upon *Rb* and *p130* loss, there is some increase in horizontal cells even in the midst of high levels of retinal degeneration [68]. This phenotype is not observed upon *Rb* and *p107* loss, implicating an important role for *p130* in horizontal cell biology distinct from that of *p107*. There is also evidence for an increased horizontal cell component in *Rb/p130* DKO compared to *Rb/p107* DKO late stage retinoblastomas [68]. The time to retinoblastoma detection and tumor penetrance differs strongly, with 100% of *Rb/p130* DKO animals developing bilateral retinoblastoma that emerge rapidly, while only a subset of *Rb/p107* DKO animals developing unilateral retinoblastoma with long latency. The kinetics of tumorigenesis suggests that there may be a difference in the number of secondary alterations that arise. A critical question is whether the tumors that eventually arise in *Rb/p107* DKO animals retain normal *p130* function, or if there is selection to evade a *p130*-induced differentiation block [67,69].

Despite differences in kinetics and cell type composition, abundant data supports a model of a common cell of origin in *Rb/p130* DKO vs. *Rb/p107* DKO retinoblastomas. First, there are similar histological characteristics including the presence of Homer-Wright rosettes [68]. *Rb/p107* DKO and *Rb/p130* DKO retinoblastomas both exhibit variable staining for different amacrine cell markers in chimeras, *NesCre1* and *Pax6 Cre* mice and each of these models exhibit the presence of some glial cells in the tumor. In both *Rb/p107* and *Rb/p130* DKO models, we have observed late proliferating cells at the extreme retina periphery. Furthermore, the pattern of tumor dissemination is similar in very advanced tumors, with invasion of the optic nerve and brain, and spread to cervical lymph nodes (although such advanced tumors are rare in *Rb/p107* DKO). Finally, secondary alteration analysis reveals that tumors in both models undergo *N-myc* amplification, suggestive of a common pathway to transformation [68].

"*p107* single" mice

While *Rb* and *p130* deletion leads to an increase in Calbindin-positive horizontal cells [68], the horizontal compartment is even further increased in another model in which *Chx10Cre* drives *Rb^{lox/lox}* deletion in *p130^{-/-}, p107^{+/-}*

- animals, termed "p107 single" [95]. The authors proposed that a differentiated horizontal cell is the retinoblastoma cell-of-origin in this model. An important result from the study is that differentiated horizontal cells with their synaptic processes divide, which was convincingly demonstrated. Interestingly, in *PNMT-Tag* mice, functional pRB family ablation in horizontal cells led to distinct effects depending on retinal topology [54]. *PNMT-Tag* expression led to tumors in peripheral retina but not in central retina, where horizontal cell death eventually occurred; it will be important to carefully examine whether peripheral vs. central horizontal cells also respond differently in *p107-single* mice. While Dyer et al (2007) conclude that the cell of origin is a horizontal cell, the possibility of another cell type that generates the late-stage tumors cannot be ruled out. The metastatic cells in *p107-single* retinoblastomas did not resemble horizontal cells either in ultrastructure or in cell marker expression, suggesting that the retinoblastomas could derive from cells that can produce both differentiated horizontal cells and non-horizontal metastatic cells or that there may be a mixed tumor phenotype with differing cells of origin. This issue is also complicated by the labeling of amacrine cell subsets by horizontal cell markers such as Calbindin and Prox1 [96]. Overall, while the *p107-single* studies clearly show that horizontal cells can divide and raise a very interesting hypothesis regarding a possible cell of origin to the tumors, deletion of these genes specifically in differentiated horizontal cells will be necessary to prove this hypothesis.

Tumor origins in human and murine retinoblastoma

Differentiated cells are not strong candidates for the cell of origin of human retinoblastoma, given the evidence of multipotent potential to human retinoblastoma cells [32], although one cannot rule out the possibility of dedifferentiation or transdifferentiation occurring. Retinoblastoma occurs over a specific window in time following eye development and is exceedingly rare in adults, suggesting that critical mutational events occur during retinal development. Also, mutation of *RB* is much more likely to occur in a proliferating cell than a post-mitotic cell as DNA replication and cell division can promote an initial gene mutation or loss of heterozygosity. Despite differences in the cell type composition of murine vs. human retinoblastomas, the cell of origin in human and mouse retinoblastoma may both be a similar multipotent cell. That is, the requirement to inactivate *p107* or *p130* in addition to *Rb* in the mouse would be expected to mask potential for the murine retinoblastoma cells to exhibit photoreceptor character, as there is widespread death of both rods and cones in the absence of *Rb* and *p107* or *Rb* and *p130* when deleted in early progenitors using *Pax6 alpha Cre* [67,68]. Instead, in murine retinoblastoma we observe the characteristics of the cells that best survive *Rb*

and *p107* or *Rb* and *p130* deletion, i.e. amacrine, Müller and horizontal cells. The specific composition of tumor cell types may be a result of the effects of *p107* or *p130* on the survival, proliferation and differentiation of the retinoblastoma cell of origin and its daughters.

Spatial topology in human retinoblastoma

Observations of early lesions at the extreme retina periphery in mouse retinoblastoma models raised the question of whether spatial differences in the localization of human retinoblastomas occur. Careful examination of retinoblastoma topology has revealed that retinoblastomas that arise in older children tend to occur at the periphery of the retina, while those that occur in younger children are typically central [97,98]. In humans, retinal proliferation ceases in a region of central retina at 14 weeks of gestation and the non-proliferative region expands to the extreme periphery by 30 weeks [26]; this central to peripheral wave of cell cycle exit and differentiation can explain some alterations in retinoblastoma topology with age of detection. Other studies have revealed that new retinoblastomas that arise in patients following treatment for primary retinoblastoma occur much more frequently at the retina periphery. For example, in one study, 15 of 17 new retinoblastomas in bilateral patients were found in the retina periphery [99] (also see [100]). These findings are less easily explained under the common view that retinogenesis ceases near the time of birth. That is, in new retinoblastomas that arise following treatment, the proliferative period of retinal development would have long since ended before the presumptive new tumor arose. Alternative possibilities include the presence of an unappreciated population of progenitors that reside in the retina periphery at a longer time following birth than previously recognized, or a population of peripheral post-mitotic cells that may be capable of transformation. Indeed, there is recent evidence of neuroprogenitors that reside at the periphery of the mammalian retina. In a primate model of myopia, experimental eyelid fusion led to the persistent proliferation of neuroprogenitor cells at the retina periphery months after birth [101]. Of note, control animals injected with BrdU also exhibited proliferation at the retina periphery, although at a much lower level than the stressed animals. These studies revealed proliferation in the juvenile primate retina and modulation with a specific stress. In *patched* heterozygous mice, persistent proliferation of cells expressing the progenitor marker *nestin* was found at the extreme retina periphery in adults, suggesting that the hedgehog pathway may be important for the late proliferating cells [102]. Furthermore, cells with properties of stem cells have been isolated from the pigmented epithelial cells of the murine and human ciliary body [103-105]. The ciliary body is a peripheral eye structure adjacent to neural retina, and close to the location where we first

observe retinoblastomas in α -Cre $Rb^{lox/lox}$ $p130^{-/-}$ or α -Cre $Rb^{lox/lox}$ $p107^{-/-}$ retinas [68]. Potential neuroprogenitor cells in the mammalian retina may exhibit some similarities to the cells of the ciliary marginal zone in fish and amphibians. In these organisms, retinogenesis continues into adulthood and stem cells clearly reside in the ciliary marginal zone at the retina periphery (reviewed in [106]). It will be critical to investigate the characteristics of the peripheral late proliferating cells in murine retinoblastoma models as this will have important implications for understanding the properties of a retinoblastoma cell of origin.

A model for retinoblastoma development

An examination of the effects of *Rb* family loss in mouse models suggests a model in which inactivation of *RB* allows the proliferative period of retinal development to be extended in the mutant cells. Upon mutation of both *Rb* and *p107* or *Rb* and *p130*, this phenotype is exacerbated in mice. This model proposes that homozygous inactivation of *RB* must occur during the normal proliferative period of retinal development, and that this event increases the chance of subsequent mutations by creating a proliferative lesion balanced by cell cycle exit and differentiation, or cell death. The loss of both copies of *RB* may increase the rate of subsequent mutations, as was found in embryonic stem (ES) cells, in which loss of *Rb* led to a dramatic increase in the rate of chromosomal alterations that result in loss of a selectable marker [107]. Loss of *Rb* can lead to chromosome segregation defects through misregulation of the expression of genes important for processes such as centrosome duplication [108,109], mitotic checkpoint control [110] or through impaired maintenance of heterochromatin [111]. In humans, the time between the end of retinal development and the appearance of retinoblastoma may be the time period in which a smoldering lesion caused by homozygous *RB* deletion during development undergoes the secondary mutations needed for tumor formation. In some cases, retinoblastoma may form from a benign precursor lesion, retinoma that exhibits some features of senescence and has recently been shown to exhibit less complex patterns of genetic alteration than adjacent retinoblastoma [112,113]. Interestingly, in retinomas, high levels of p130 were found, which were not observed in adjacent retinoblastoma, suggesting that evasion of p130 might be important for progression of human retinoma to retinoblastoma [112]. One of the essential current questions is the nature of the block to proliferation/tumor expansion that must be overcome even upon homozygous *RB* inactivation. Specifically, is this a differentiation block, or must cell death or other processes be overcome? Examination of the nature of secondary alterations will be needed to shed light on this question.

Secondary genetic alterations in retinoblastoma

The two-hit hypothesis suggests that the first few years following birth reflects the time-interval for homozygous *RB* mutation [1]. However, there is evidence that *RB* inactivation is not sufficient for retinoblastoma, as cytogenetic studies have revealed consistent chromosomal abnormalities in addition to *RB* deletion [114]. Early cytogenetic studies have been extended by comparative genomic hybridization (CGH) and array-CGH studies. Pooled data across 6 studies reveal recurrent gain in 6p (54%), 1q (53%), 2p (34%) and loss of 16q (32%), suggesting that these regions may harbor oncogenes and tumor suppressor genes, respectively [115-120], reviewed in [121]. The vast majority of these data are from low-resolution studies; the advent of high-resolution oligonucleotide based array-CGH promises to pinpoint minimal regions and identify new, focal regions of change. In murine metastatic retinoblastomas lacking *Rb* and *p130*, array CGH revealed recurrent whole chromosomal gains at chromosome 1 (with synteny to the minimal region of gain in human retinoblastoma at human 1q31-32) and 12 (with synteny to the minimal region of gain at human 2p24) [68]. Such findings of overlapping regions of frequent chromosomal alterations in both murine and human retinoblastoma are encouraging as they help to validate the α -Cre $Rb/p130$ DKO mouse model. While alterations in regions syntenic to human 6p and 16q were not observed in α -Cre $Rb/p130$ DKO retinoblastomas, larger studies are needed, and it is possible that loss of p130 in the murine model may negate selection for 6p gain or 16q loss. Indeed, *RBL2* (*p130*) lies at 16q12 and is a good candidate tumor suppressor in this region in humans [121]. Genes in the minimal region of gain at human 6p22 include *DEK* as well as an interesting candidate, *E2F3*, which conceivably could antagonize p130 upon overexpression. Use of mouse models will certainly help in defining the critical genes in these regions, as mouse/human comparisons have revealed highly concordant genomic alterations in other tumor types and have allowed for the identification and validation critical cancer-contributing genes [122,123]. As the topic of genomic alterations in retinoblastoma has recently been comprehensively reviewed [121], here, I will briefly touch upon on the human 1q31-32 and 2p candidate regions that undergo gain or amplification in both murine and human retinoblastomas.

Human 2p gain/N-MYC amplification

The most well characterized secondary alteration in human retinoblastoma is gain or amplification of a region of 2p that includes the *N-MYC* locus [118,124-126]. It is not formally known that *N-MYC* is the gene in the amplicon selected for increased copy number, as other genes are co-amplified, including the DEAD box gene *DDX1*. However, in α -Cre $Rb^{lox/lox}$ $p130^{-/-}$ metastatic retinoblastomas

(3 of 16 metastases), amplicons containing *N-myc* were also observed, ranging from 450 kb to 3.3 MB, and the only known gene in the minimal region of amplification was *N-myc* [68]. This result illustrates the power of high density array-CGH analyses to resolve regions of alteration to single genes and reveals the similarities between human and mouse retinoblastomas. In both murine and human retinoblastoma, low level gain of *N-myc/N-MYC* is found more frequently than high level amplification. The fact that *N-Myc* amplification is enriched in metastatic α -*Cre Rb^{lox/lox} p130^{-/-}* retinoblastoma suggests that this event contributes to formation of more aggressive tumors but how this is mediated is unknown. Genetic inactivation of *N-myc* in the developing retina has revealed a critical role for this gene in progenitor cell proliferation; this is in part mediated by regulation of p27 levels [127]. Examination of interactions between *Rb* and *N-myc* in the developing retina and in retinoblastoma models should help us to understand why these mutations synergize in tumorigenesis and to identify the critical *N-myc* target genes.

MDM4 and the p53 pathway in retinoblastoma

Many cytogenetic studies and CGH experiments have demonstrated recurrent frequent gains in 1q [114,121]. While the regions of change typically include large regions of 1q, smaller regions of gain in some tumors have been used to define minimal common regions. Zielinski et al (2005) noted a minimal region centered at 1q32.1-32.2, that included the genes *MDM4* and *GAC1*, and they also identified a second common minimal region of gain at 1q22 [120]. *MDM4* is related to *MDM2* and both genes cooperate to inhibit p53 function, with *MDM4* an inhibitor of p53 transcriptional activity [128]. Laurie et al [59] showed by FISH that *MDM4* undergoes copy number increase and is overexpressed in retinoblastomas. They report that 65% of human retinoblastomas had extra copies of *MDM4* and 10% exhibited extra copies of *MDM2*. Furthermore, transfection of *MDM4* plasmid DNA into newborn retinas *in vivo* led to more rapid tumorigenesis in the α -*Cre Rb/p107 DKO* model. p53 is a good candidate effector downstream of *MDM4* as homozygous p53 loss accelerated retinoblastoma development *in vivo* in *Chx10-Cre; Rb^{lox/lox} p53^{-/-}; p107^{-/-}* animals compared to animals with wild-type p53 [70,129]. In contrast to these findings, in animals with inactivation of *Rb* on a p53^{-/-} background, (*NesCre1 Rb lox/lox p53^{-/-}* mice) retinoblastomas did not result [69], suggesting that p53 loss can impact upon retinoblastomas that have already been initiated, but that inactivation of a second pocket protein in addition to *Rb* is still critical. Based on experiments in culture using retinal explants, the authors suggest that suppression of p53-dependent apoptosis is crucial [59]. However, murine retinal explants lacking *Rb* exhibit very low levels of apoptosis [73] compared to the high levels observed in *Rb^{-/-}* retinas *in vivo* (Table 2) and therefore may not be an ideal

correlate of *Rb*-dependent apoptosis *in vivo*. Indeed, *Rb/p53* compound mutation did not lead to suppression of cell death associated with *Rb* inactivation *in vivo* [69]. Also, in chimeras with cells lacking *Rb* and *p107*, expression of a dominant negative p53 in *Rb/p107 DKO* photoreceptors using an IRBP-p53DD transgene did not rescue photoreceptor apoptosis *in vivo* [65]. It is also possible that p53 loss may contribute to retinoblastoma through deregulation of p53 effectors that control the cell cycle or maintain genomic stability. An absence of direct p53 mutations in human retinoblastoma suggests that other effectors downstream of *MDM2/MDM4* may be important. Candidates include the other p53 family members p63 and p73, as well as targets such as Numb and p21 [130-132].

While *MDM4* is an excellent candidate retinoblastoma oncogene gene on 1q, an important question is whether there are other genes on chromosome 1q that drive selection for 1q gain. Findings of recurrent focal regions of high-level gene amplification at 1q21 and 1q22 [118,133,120] and the identification of additional candidates in the 1q32 minimal region of gain such as the mitotic kinesin *Kif14* [134,135] suggest that 1q harbors multiple oncogenes. Unlike gliomas, which exhibit high-level focal amplifications of *MDM4* [136] examination of a large panel of retinoblastomas with 1q gain revealed low-level *MDM4* gain in retinoblastoma [133]. Low-level *MDM4* gain, even of a single copy may allow a critical threshold of *MDM4* signaling to be reached and be physiologically important for tumor development, but other 1q candidates should also be investigated. High-resolution array-CGH experiments using human retinoblastoma samples will help to delineate the regions of focal high-level gene amplifications on 1q most likely to harbor critical oncogenes.

The new data on possible p53 pathway involvement in retinoblastoma provides interesting areas for future research and the potential for novel, targeted therapy (reviewed in [137]). Importantly, the addition of Nutlin, an *MDM4/MDM2* antagonist led to death of retinoblastoma cell lines and synergized with traditional chemotherapy in an orthotopic retinoblastoma mouse model [58,59]. It is clear that radiotherapy can synergize with constitutional *RB* mutation in increasing secondary tumors in patients [12]. The long term effects of systemic chemotherapy on the incidence of secondary tumors in germline *RB* mutant patients are not yet known, but it is conceivable that chemotherapy could contribute to the development of mutations that cooperate with *RB* mutation at sites other than the eye. Also, systemic chemotherapy can lead to debilitating side effects. Thus, localized therapy based on the genetics of known frequent alterations in retinoblastoma combined with localized chemo-

therapy may provide a safer, effective treatment. It is therefore essential that this pathway be better understood.

Summary

Research into retinoblastoma has revealed a great deal about a malignant eye cancer, and has also led to many general insights into the general mechanisms of tumor suppression. Early genomic analyses of murine retinoblastoma lacking *Rb* and *p130* have revealed secondary alterations similar to human retinoblastoma, suggesting that the steps to tumorigenesis in the murine and human retina are similar. Mouse models will be particularly powerful for testing which candidate genes are important for retinoblastoma progression. The novel models provide valuable tools to help us understand the *in vivo* function of pRB, to elucidate the properties of a cancer cell of origin and to test preclinical therapies. We are now poised to gain important insights into the steps between *RB* inactivation in a developing retinal cell and the progression towards retinoblastoma.

Acknowledgements

I thank Julien Sage, Meg McLaughlin and Shizuo Mukai for helpful discussions and comments on the manuscript as well as Xuemei Zhu and Cheryl M. Craft for the antibody to M-opsin.

References

- Knudson AG Jr: **Mutation and cancer: statistical study of retinoblastoma.** *Proc Natl Acad Sci USA* 1971, **68**:820-823.
- Nichols KE, Houseknecht MD, Godmilow L, Bunin G, Shields C, Meadows A, Ganguly A: **Sensitive multistep clinical molecular screening of 180 unrelated individuals with retinoblastoma detects 36 novel mutations in the Rb1 gene.** *Hum Mutat* 2005, **25**:566-574.
- Richter S, Vandezande K, Chen N, Zhang K, Sutherland J, Anderson J, Han L, Panton R, Branco P, Gallie B: **Sensitive and efficient detection of Rb1 gene mutations enhances care for families with retinoblastoma.** *Am J Hum Genet* 2003, **72**:253-269.
- Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP: **A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma.** *Nature* 1986, **323**:643-646.
- Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, Lee WH: **Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma.** *Proc Natl Acad Sci USA* 1990, **87**:7762-7766.
- Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ: **Abnormalities in structure and expression of the human retinoblastoma gene in SCLC.** *Science* 1988, **241**:353-357.
- Horowitz JM, Park SH, Bogenmann E, Cheng JC, Yandell DW, Kaye FJ, Minna JD, Dryja TP, Weinberg RA: **Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells.** *Proc Natl Acad Sci USA* 1990, **87**:2775-2779.
- Stratton MR, Williams S, Fisher C, Ball A, Westbury G, Gusterson BA, Fletcher CD, Knight JC, Fung YK, Reeves BR, et al.: **Structural alterations of the Rb1 gene in human soft tissue tumours.** *Br J Cancer* 1989, **60**:202-205.
- Venter DJ, Bevan KL, Ludwig RL, Riley TE, Jat PS, Thomas DG, Noble MD: **Retinoblastoma gene deletions in human glioblastomas.** *Oncogene* 1991, **6**:445-448.
- Eng C, Li FP, Abramson DH, Ellsworth RM, Wong FL, Goldman MB, Seddon J, Tarbell N, Boice JD Jr: **Mortality from second tumors among long-term survivors of retinoblastoma.** *J Natl Cancer Inst* 1993, **85**:1121-1128.
- Fletcher O, Easton D, Anderson K, Gilham C, Jay M, Peto J: **Lifetime risks of common cancers among retinoblastoma survivors.** *J Natl Cancer Inst* 2004, **96**:357-363.
- Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M, Li FP, Fraumeni JF Jr: **Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up.** *J Clin Oncol* 2005, **23**:2272-2279.
- Kivela T: **Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma.** *J Clin Oncol* 1999, **17**:1829-1837.
- Marcus DM, Brooks SE, Leff G, McCormick R, Thompson T, Anfinson S, Lasudry J, Albert DM: **Trilateral retinoblastoma: insights into histogenesis and management.** *Surv Ophthalmol* 1998, **43**:59-70.
- Classon M, Harlow E: **The retinoblastoma tumour suppressor in development and cancer.** *Nat Rev Cancer* 2002, **2**:910-917.
- laquinta PJ, Lees JA: **Life and death decisions by the E2F transcription factors.** *Curr Opin Cell Biol* 2007, **19**:649-657.
- Lee EY, Cam H, Ziebold U, Rayman JB, Lees JA, Dynlacht BD: **E2F4 loss suppresses tumorigenesis in Rb mutant mice.** *Cancer Cell* 2002, **2**:463-472.
- Takahashi Y, Rayman JB, Dynlacht BD: **Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression.** *Genes Dev* 2000, **14**:804-816.
- Litovchick L, Sadasivam S, Florens L, Zhu X, Swanson SK, Velmurugan S, Chen R, Washburn MP, Liu XS, DeCaprio JA: **Evolutionarily conserved multisubunit RBL2/p130 and E2F4 protein complex represses human cell cycle-dependent genes in quiescence.** *Mol Cell* 2007, **26**:539-551.
- Pilkinton M, Sandoval R, Colamonici OR: **Mammalian Mip/LIN-9 interacts with either the p107, p130/E2F4 repressor complex or B-Myb in a cell cycle-phase-dependent context distinct from the Drosophila dREAM complex.** *Oncogene* 2007, **26**:7535-7543.
- Schmit F, Korenjak M, Mannefeld M, Schmitt K, Franke C, von Eyss B, Gargra S, Hanel F, Brehm A, Gaubatz S: **LINC, a human complex that is related to pRB-containing complexes in invertebrates regulates the expression of G2/M genes.** *Cell Cycle* 2007, **6**:1903-1913.
- Carreira S, Goodall J, Aksan I, La Rocca SA, Galibert MD, Denat L, Larue L, Goding CR: **Mitf cooperates with Rb1 and activates p21/Cip1 expression to regulate cell cycle progression.** *Nature* 2005, **433**:764-769.
- Chen PL, Riley DJ, Chen-Kiang S, Lee WH: **Retinoblastoma protein directly interacts with and activates the transcription factor NF-IL6.** *Proc Natl Acad Sci USA* 1996, **93**:465-469.
- Gu W, Schneider JW, Condorelli G, Kaushal S, Mahdavi V, Nadal-Ginard B: **Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation.** *Cell* 1993, **72**:309-324.
- Thomas DM, Carty SA, Piscopo DM, Lee JS, Wang WF, Forrester WC, Hinds PW: **The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation.** *Mol Cell* 2001, **8**:303-316.
- Provis JM, van Driel D, Billson FA, Russell P: **Development of the human retina: patterns of cell distribution and redistribution in the ganglion cell layer.** *J Comp Neurol* 1985, **233**:429-451.
- Young RW: **Cell proliferation during postnatal development of the retina in the mouse.** *Brain Res* 1985, **353**:229-239.
- Chow RL, Lang RA: **Early eye development in vertebrates.** *Annu Rev Cell Dev Biol* 2001, **17**:255-296.
- Turner DL, Snyder EY, Cepko CL: **Lineage-independent determination of cell type in the embryonic mouse retina.** *Neuron* 1990, **4**:833-845.
- Turner DL, Cepko CL: **A common progenitor for neurons and glia persists in rat retina late in development.** *Nature* 1987, **328**:131-136.
- Maat-Kievit JA, Oepkes D, Hartwig NG, Vermeij-Keers C, van Kamp IL, Kamp JJ van de: **A large retinoblastoma detected in a fetus at 21 weeks of gestation.** *Prenat Diagn* 1993, **13**:377-384.
- Kyritsis AP, Tsokos M, Triche TJ, Chader GJ: **Retinoblastoma—origin from a primitive neuroectodermal cell?** *Nature* 1984, **307**:471-473.
- Ts'o MO, Fine BS, Zimmerman LE: **The nature of retinoblastoma. II. Photoreceptor differentiation: an electron microscopic study.** *Am J Ophthalmol* 1970, **69**:350-359.
- Ts'o MO, Zimmerman LE, Fine BS: **The nature of retinoblastoma. I. Photoreceptor differentiation: a clinical and histopathologic study.** *Am J Ophthalmol* 1970, **69**:339-349.

35. Donoso LA, Hamm H, Dietzschold B, Augsburger JJ, Shields JA, Arbizu V: **Rhodopsin and retinoblastoma. A monoclonal antibody histopathologic study.** *Arch Ophthalmol* 1986, **104**:111-113.
36. Vrabec T, Arbizu V, Adamus G, McDowell JH, Hargrave PA, Donoso LA: **Rod cell-specific antigens in retinoblastoma.** *Arch Ophthalmol* 1989, **107**:1061-1063.
37. Gonzalez-Fernandez F, Lopes MB, Garcia-Fernandez JM, Foster RG, De Grip WJ, Rosemberg S, Newman SA, VandenBerg SR: **Expression of developmentally defined retinal phenotypes in the histogenesis of retinoblastoma.** *Am J Pathol* 1992, **141**:363-375.
38. Bogenmann E, Lochrie MA, Simon MI: **Cone cell-specific genes expressed in retinoblastoma.** *Science* 1988, **240**:76-78.
39. Hurwitz RL, Bogenmann E, Font RL, Holcombe V, Clark D: **Expression of the functional cone phototransduction cascade in retinoblastoma.** *J Clin Invest* 1990, **85**:1872-1878.
40. Tsokos M, Kyritsis AP, Chader GJ, Triche TJ: **Differentiation of human retinoblastoma in vitro into cell types with characteristics observed in embryonal or mature retina.** *Am J Pathol* 1986, **123**:542-552.
41. Gallie BL, Campbell C, Devlin H, Duckett A, Squire JA: **Developmental basis of retinal-specific induction of cancer by RB mutation.** *Cancer Res* 1999, **59**:1731s-1735s.
42. Nork TM, Schwartz TL, Doshi HM, Millecchia LL: **Retinoblastoma. Cell of origin.** *Arch Ophthalmol* 1995, **113**:791-802.
43. Schroder HD: **Immunohistochemical demonstration of glial markers in retinoblastomas.** *Virchows Arch A Pathol Anat Histopathol* 1987, **41**:67-72.
44. Perentes E, Herbolt CP, Rubinstein LJ, Herman MM, Uffer S, Donoso LA, Collins VP: **Immunohistochemical characterization of human retinoblastomas in situ with multiple markers.** *Am J Ophthalmol* 1987, **103**:647-658.
45. Seigel GM, Hackam AS, Ganguly A, Mandell LM, Gonzalez-Fernandez F: **Human embryonic and neuronal stem cell markers in retinoblastoma.** *Mol Vis* 2007, **13**:823-832.
46. Zhong X, Li Y, Peng F, Huang B, Lin J, Zhang W, Zheng J, Jiang R, Song G, Ge J: **Identification of tumorigenic retinal stem-like cells in human solid retinoblastomas.** *Int J Cancer* 2007, **121**:2125-2131.
47. Windle JJ, Albert DM, O'Brien JM, Marcus DM, Disteche CM, Bernards R, Mellon PL: **Retinoblastoma in transgenic mice.** *Nature* 1990, **343**:665-669.
48. Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, DeCaprio JA, Weinberg RA: **Enumeration of the simian virus 40 early region elements necessary for human cell transformation.** *Mol Cell Biol* 2002, **22**:2111-2123.
49. al-Ubaidi MR, Font RL, Quiambao AB, Keener MJ, Liou GI, Overbeek PA, Baehr W: **Bilateral retinal and brain tumors in transgenic mice expressing simian virus 40 large T antigen under control of the human interphotoreceptor retinoid-binding protein promoter.** *J Cell Biol* 1992, **119**:1681-1687.
50. Howes KA, Lasudry JG, Albert DM, Windle JJ: **Photoreceptor cell tumors in transgenic mice.** *Invest Ophthalmol Vis Sci* 1994, **35**:342-351.
51. Marcus DM, Lasudry JG, Carpenter JL, Windle J, Howes KA, al-Ubaidi MR, Baehr W, Overbeek PA, Font RL, Albert DM: **Trilateral tumors in four different lines of transgenic mice expressing SV40 T-antigen.** *Invest Ophthalmol Vis Sci* 1996, **37**:392-396.
52. Liou GI, Wang M, Matragoon S: **Timing of interphotoreceptor retinoid-binding protein (IRBP) gene expression and hypomethylation in developing mouse retina.** *Dev Biol* 1994, **161**:345-356.
53. Hammang JP, Baetge EE, Behringer RR, Brinster RL, Palmiter RD, Messing A: **Immortalized retinal neurons derived from SV40 T-antigen-induced tumors in transgenic mice.** *Neuron* 1990, **4**:775-782.
54. Hammang JP, Behringer RR, Baetge EE, Palmiter RD, Brinster RL, Messing A: **Oncogene expression in retinal horizontal cells of transgenic mice results in a cascade of neurodegeneration.** *Neuron* 1993, **10**:1197-1209.
55. Howes KA, Ransom N, Papermaster DS, Lasudry JG, Albert DM, Windle JJ: **Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53.** *Genes Dev* 1994, **8**:1300-1310.
56. Mills MD, Windle JJ, Albert DM: **Retinoblastoma in transgenic mice: models of hereditary retinoblastoma.** *Surv Ophthalmol* 1999, **43**:508-518.
57. Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, El-Naggar AK, Multani A, Chang S, Lozano G: **Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice.** *Nat Genet* 2004, **36**:63-68.
58. Elison JR, Cobrinik D, Claros N, Abramson DH, Lee TC: **Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells.** *Arch Ophthalmol* 2006, **124**:1269-1275.
59. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, Wilson M, Rodriguez-Galindo C, Quarto M, Francoz S, Mendrysa SM, Guy RK, Marine JC, Jochemsen AG, Dyer MA: **Inactivation of the p53 pathway in retinoblastoma.** *Nature* 2006, **444**:61-66.
60. Clarke AR, Maandag ER, van Roon M, Lugt NM van der, Valk M van der, Hooper ML, Berns A, te Riele H: **Requirement for a functional Rb-1 gene in murine development.** *Nature* 1992, **359**:328-330.
61. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA: **Effects of an Rb mutation in the mouse.** *Nature* 1992, **359**:295-300.
62. Lee EY, Chang CY, Hu N, Wang YC, Lai CC, Herrup K, Lee WH, Bradley A: **Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis.** *Nature* 1992, **359**:288-294.
63. Maandag EC, Valk M van der, Vlaar M, Feltkamp C, O'Brien J, van Roon M, Lugt N van der, Berns A, te Riele H: **Developmental rescue of an embryonic-lethal mutation in the retinoblastoma gene in chimeric mice.** *Embo J* 1994, **13**:4260-4268.
64. Williams BO, Schmitt EM, Remington L, Bronson RT, Albert DM, Weinberg RA, Jacks T: **Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences.** *Embo J* 1994, **13**:4251-4259.
65. Robanus-Maandag E, Dekker M, Valk M van der, Carrozza ML, Jeanny JC, Dannenberg JH, Berns A, te Riele H: **p107 is a suppressor of retinoblastoma development in pRb-deficient mice.** *Genes Dev* 1998, **12**:1599-1609.
66. Vooijs M, te Riele H, Valk M van der, Berns A: **Tumor formation in mice with somatic inactivation of the retinoblastoma gene in interphotoreceptor retinoid binding protein-expressing cells.** *Oncogene* 2002, **21**:4635-4645.
67. Chen D, Livne-bar I, Vanderluit JL, Slack RS, Agochiya M, Bremner R: **Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma.** *Cancer Cell* 2004, **5**:539-551.
68. MacPherson D, Conkrite K, Tam M, Mukai S, Mu D, Jacks T: **Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification.** *Embo J* 2007, **26**:784-794.
69. MacPherson D, Sage J, Kim T, Ho D, McLaughlin ME, Jacks T: **Cell type-specific effects of Rb deletion in the murine retina.** *Genes Dev* 2004, **18**:1681-1694.
70. Zhang J, Schweers B, Dyer MA: **The first knockout mouse model of retinoblastoma.** *Cell Cycle* 2004, **3**:952-959.
71. Dannenberg JH, Schuijff L, Dekker M, Valk M van der, te Riele H: **Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130.** *Genes Dev* 2004, **18**:2952-2962.
72. Wu L, de Bruin A, Saavedra HI, Starovic M, Trimboli A, Yang Y, Opavska J, Wilson P, Thompson JC, Ostrowski MC, Rosol TJ, Woollett LA, Weinstein M, Cross JC, Robinson ML, Leone G: **Extra-embryonic function of Rb is essential for embryonic development and viability.** *Nature* 2003, **421**:942-947.
73. Zhang J, Gray J, Wu L, Leone G, Rowan S, Cepko CL, Zhu X, Craft CM, Dyer MA: **Rb regulates proliferation and rod photoreceptor development in the mouse retina.** *Nat Genet* 2004, **36**:351-360.
74. Marquardt T, Ashery-Padan R, Andrejewski N, Scardigli R, Guillemot F, Gruss P: **Pax6 is required for the multipotent state of retinal progenitor cells.** *Cell* 2001, **105**:43-55.
75. Saavedra HI, Wu L, de Bruin A, Timmers C, Rosol TJ, Weinstein M, Robinson ML, Leone G: **Specificity of E2F1, E2F2, and E2F3 in mediating phenotypes induced by loss of Rb.** *Cell Growth Differ* 2002, **13**:215-225.
76. Dyer MA, Bremner R: **The search for the retinoblastoma cell of origin.** *Nat Rev Cancer* 2005, **5**:91-101.
77. Donovan SL, Dyer MA: **Developmental defects in Rb-deficient retinae.** *Vision Res* 2004, **44**:3323-3333.

78. Johnson DA, Donovan SL, Dyer MA: **Mosaic deletion of Rb arrests rod differentiation and stimulates ectopic synaptogenesis in the mouse retina.** *J Comp Neurol* 2006, **498**:112-128.
79. Chen D, Opavsky R, Pacal M, Tanimoto N, Wenzel P, Seeliger MW, Leone G, Bremner R: **Rb-Mediated Neuronal Differentiation through Cell-Cycle-Independent Regulation of E2f3a.** *PLoS Biol* 2007, **5**:e179.
80. Liu IS, Chen JD, Ploder L, Vidgen D, Kooy D van der, Kalnins VI, McInnes RR: **Developmental expression of a novel murine homeobox gene (Chx10): evidence for roles in determination of the neuroretina and inner nuclear layer.** *Neuron* 1994, **13**:377-393.
81. Cepko CL, Austin CP, Yang X, Alexiades M, Ezzeddine D: **Cell fate determination in the vertebrate retina.** *Proc Natl Acad Sci USA* 1996, **93**:589-595.
82. Chau BN, Wang JY: **Coordinated regulation of life and death by RB.** *Nat Rev Cancer* 2003, **3**:130-138.
83. Hanahan D, Weinberg RA: **The hallmarks of cancer.** *Cell* 2000, **100**:57-70.
84. Donovan S, Schweers B, Martins R, Johnson D, Dyer MA: **Compensation by tumor suppressor genes during retinal development in mice and humans.** *BMC Biol* 2006, **4**:14.
85. Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RT, Elledge SJ, Weinberg RA: **Cyclin D1 provides a link between development and oncogenesis in the retina and breast.** *Cell* 1995, **82**:621-630.
86. Levine EM, Close J, Fero M, Ostrovsky A, Reh TA: **p27(Kip1) regulates cell cycle withdrawal of late multipotent progenitor cells in the mammalian retina.** *Dev Biol* 2000, **219**:299-314.
87. Cunningham JJ, Levine EM, Zindy F, Goloubeva O, Roussel MF, Smeyne RJ: **The cyclin-dependent kinase inhibitors p19(Ink4d) and p27(Kip1) are coexpressed in select retinal cells and act cooperatively to control cell cycle exit.** *Mol Cell Neurosci* 2002, **19**:359-374.
88. Masland RH: **The fundamental plan of the retina.** *Nat Neurosci* 2001, **4**:877-886.
89. Johnson DA, Zhang J, Frase S, Wilson M, Rodriguez-Galindo C, Dyer MA: **Neuronal differentiation and synaptogenesis in retinoblastoma.** *Cancer Res* 2007, **67**:2701-2711.
90. Dimaras H, Gallie BL: **The p75 NTR neurotrophin receptor is a tumor suppressor in human and murine retinoblastoma development.** *Int J Cancer* 2008, **122**:2023-2029.
91. Kivela T, Virtanen I, Marcus DM, O'Brien JM, Carpenter JL, Brauner E, Tarkkanen A, Albert DM: **Neuronal and glial properties of a murine transgenic retinoblastoma model.** *Am J Pathol* 1991, **138**:1135-1148.
92. Balmer A, Zografos L, Munier F: **Diagnosis and current management of retinoblastoma.** *Oncogene* 2006, **25**:5341-5349.
93. Jubran RF, Erdreich-Epstein A, Butturini A, Murphree AL, Villablanca JG: **Approaches to treatment for extraocular retinoblastoma: Children's Hospital Los Angeles experience.** *J Pediatr Hematol Oncol* 2004, **26**:31-34.
94. Gallie BL, Zhao J, Vandezande K, White A, Chan HS: **Global issues and opportunities for optimized retinoblastoma care.** *Pediatr Blood Cancer* 2007, **49**:1083-1090.
95. Ajioka I, Martins RA, Bayazitov IT, Donovan S, Johnson DA, Frase S, Cicero SA, Boyd K, Zakharenko SS, Dyer MA: **Differentiated horizontal interneurons clonally expand to form metastatic retinoblastoma in mice.** *Cell* 2007, **131**:378-390.
96. Dyer MA, Livesey FJ, Cepko CL, Oliver G: **Prox1 function controls progenitor cell proliferation and horizontal cell genesis in the mammalian retina.** *Nat Genet* 2003, **34**:53-58.
97. Abramson DH, Gombos DS: **The topography of bilateral retinoblastoma lesions.** *Retina* 1996, **16**:232-239.
98. Brinkert AW, Moll AC, Jager MJ, Den Otter W, Koten JW, Faber JA, Tan KE: **Distribution of tumors in the retina in hereditary retinoblastoma patients.** *Ophthalmic Genet* 1998, **19**:63-67.
99. Roysarkar TK, Biswas J, Gopal L: **New tumours in non-enucleated eyes of bilateral retinoblastoma patients.** *Indian J Ophthalmol* 1994, **42**:19-22.
100. Salmonsens PC, Ellsworth RM, Kitchin FD: **The occurrence of new retinoblastomas after treatment.** *Ophthalmology* 1979, **86**:837-843.
101. Tkatchenko AV, Walsh PA, Tkatchenko TV, Gustincich S, Raviola E: **Form deprivation modulates retinal neurogenesis in primate experimental myopia.** *Proc Natl Acad Sci USA* 2006, **103**:4681-4686.
102. Moshiri A, Reh TA: **Persistent progenitors at the retinal margin of ptc⁺ mice.** *J Neurosci* 2004, **24**:229-237.
103. Ahmad I, Tang L, Pham H: **Identification of neural progenitors in the adult mammalian eye.** *Biochem Biophys Res Commun* 2000, **270**:517-521.
104. Coles BL, Angenieux B, Inoue T, Del Rio-Tsonis K, Spence JR, McInnes RR, Arsenijevic Y, Kooy D van der: **Facile isolation and the characterization of human retinal stem cells.** *Proc Natl Acad Sci USA* 2004, **101**:15772-15777.
105. Tropepe V, Coles BL, Chiasson BJ, Horsford DJ, Elia AJ, McInnes RR, Kooy D van der: **Retinal stem cells in the adult mammalian eye.** *Science* 2000, **287**:2032-2036.
106. Moshiri A, Close J, Reh TA: **Retinal stem cells and regeneration.** *Int J Dev Biol* 2004, **48**:1003-1014.
107. Zheng L, Flesken-Nikitin A, Chen PL, Lee WH: **Deficiency of Retinoblastoma gene in mouse embryonic stem cells leads to genetic instability.** *Cancer Res* 2002, **62**:2498-2502.
108. Iovino F, Lentini L, Amato A, Di Leonardo A: **RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts.** *Mol Cancer* 2006, **5**:38.
109. Meraldi P, Lukas J, Fry AM, Bartek J, Nigg EA: **Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A.** *Nat Cell Biol* 1999, **1**:88-93.
110. Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Corcion-Cardo C: **Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control.** *Nature* 2004, **430**:797-802.
111. Gonzalo S, Garcia-Cao M, Fraga MF, Schotta G, Peters AH, Cotter SE, Eguia R, Dean DC, Esteller M, Jenuwein T, Blasco MA: **Role of the Rb1 family in stabilizing histone methylation at constitutive heterochromatin.** *Nat Cell Biol* 2005, **7**:420-428.
112. Dimaras H, Khetan V, Halliday W, Orlic M, Prigoda NL, Piovesan B, Marrano P, Corson TW, Eagle RC Jr, Squire JA, Gallie BL: **Loss of Rb1 induces non-proliferative retinoma; increasing genomic instability correlates with progression to retinoblastoma.** *Hum Mol Genet* 2008.
113. Gallie BL, Ellsworth RM, Abramson DH, Phillips RA: **Retinoma: spontaneous regression of retinoblastoma or benign manifestation of the mutation?** *Br J Cancer* 1982, **45**:513-521.
114. Squire J, Gallie BL, Phillips RA: **A detailed analysis of chromosomal changes in heritable and non-heritable retinoblastoma.** *Hum Genet* 1985, **70**:291-301.
115. Chen D, Gallie BL, Squire JA: **Minimal regions of chromosomal imbalance in retinoblastoma detected by comparative genomic hybridization.** *Cancer Genet Cytogenet* 2001, **129**:57-63.
116. Herzog S, Lohmann DR, Buiting K, Schuler A, Horsthemke B, Rehder H, Rieder H: **Marked differences in unilateral isolated retinoblastomas from young and older children studied by comparative genomic hybridization.** *Hum Genet* 2001, **108**:98-104.
117. Lillington DM, Kingston JE, Coen PG, Price E, Hungerford J, Domizio P, Young BD, Onadim Z: **Comparative genomic hybridization of 49 primary retinoblastoma tumors identifies chromosomal regions associated with histopathology, progression, and patient outcome.** *Genes Chromosomes Cancer* 2003, **36**:121-128.
118. Mairal A, Pinglier E, Gilbert E, Peter M, Validire P, Desjardins L, Doz F, Aurias A, Couturier J: **Detection of chromosome imbalances in retinoblastoma by parallel karyotype and CGH analyses.** *Genes Chromosomes Cancer* 2000, **28**:370-379.
119. Wal JE van der, Hermsen MA, Gille HJ, Schouten-Van Meeteren NY, Moll AC, Imhof SM, Meijer GA, Baak JP, Valk P van der: **Comparative genomic hybridisation divides retinoblastomas into a high and a low level chromosomal instability group.** *J Clin Pathol* 2003, **56**:26-30.
120. Zielinski B, Gratijs S, Toedt G, Mendrzyk F, Stange DE, Radwimmer B, Lohmann DR, Lichter P: **Detection of chromosomal imbalances in retinoblastoma by matrix-based comparative genomic hybridization.** *Genes Chromosomes Cancer* 2005, **43**:294-301.
121. Corson TW, Gallie BL: **One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma.** *Genes Chromosomes Cancer* 2007, **46**:617-634.
122. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A, O'Neil J, Gutierrez A, Ivanova E, Perna I, Lin E, Mani V, Jiang S,

- McNamara K, Zaghlul S, Edkins S, Stevens C, Brennan C, Martin ES, Wiedemeyer R, Kabbarah O, Nogueira C, Histen G, Aster J, Mansour M, Duke V, Foroni L, Fielding AK, Goldstone AH, Rowe JM, Wang YA, Look AT, Stratton MR, Chin L, Futreal PA, DePinho RA: **Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers.** *Nature* 2007, **447**:966-971.
123. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D, Lucito R, Powers S, Lowe SW: **Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach.** *Cell* 2006, **125**:1253-1267.
124. Lee WH, Murphree AL, Benedict WF: **Expression and amplification of the N-myc gene in primary retinoblastoma.** *Nature* 1984, **309**:458-460.
125. Lillington DM, Goff LK, Kingston JE, Onadim Z, Price E, Domizio P, Young BD: **High level amplification of N-MYC is not associated with adverse histology or outcome in primary retinoblastoma tumours.** *Br J Cancer* 2002, **87**:779-782.
126. Squire JA, Thorner PS, Weitzman S, Maggi JD, Dirks P, Doyle J, Hale M, Godbout R: **Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma.** *Oncogene* 1995, **10**:1417-1422.
127. Martins RA, Zindy F, Donovan S, Zhang J, Pounds S, Wey A, Knoepfler PS, Eisenman RN, Roussel MF, Dyer MA: **N-myc coordinates retinal growth with eye size during mouse development.** *Genes Dev* 2008, **22**:179-193.
128. Toledo F, Wahl GM: **Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.** *Nat Rev Cancer* 2006, **6**:909-923.
129. Dyer MA, Rodriguez-Galindo C, Wilson MW: **Use of preclinical models to improve treatment of retinoblastoma.** *PLoS Med* 2005, **2**:e332.
130. Jin Y, Zeng SX, Sun XX, Lee H, Blattner C, Xiao Z, Lu H: **MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2.** *Mol Cell Biol* 2008, **28**:1218-1229.
131. Juven-Gershon T, Shifman O, Unger T, Elkeles A, Haupt Y, Oren M: **The Mdm2 oncoprotein interacts with the cell fate regulator Numb.** *Mol Cell Biol* 1998, **18**:3974-3982.
132. Watson IR, Blanch A, Lin DC, Ohh M, Irwin MS: **Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function.** *J Biol Chem* 2006, **281**:34096-34103.
133. Gratiás S, Schuler A, Hitpass LK, Stephan H, Rieder H, Schneider S, Horsthemke B, Lohmann DR: **Genomic gains on chromosome 1q in retinoblastoma: consequences on gene expression and association with clinical manifestation.** *Int J Cancer* 2005, **116**:555-563.
134. Bowles E, Corson TW, Bayani J, Squire JA, Wong N, Lai PB, Gallie BL: **Profiling genomic copy number changes in retinoblastoma beyond loss of RB1.** *Genes Chromosomes Cancer* 2007, **46**:118-129.
135. Corson TW, Huang A, Tsao MS, Gallie BL: **KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers.** *Oncogene* 2005, **24**:4741-4753.
136. Riemenschneider MJ, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus JA, Schlegel U, Reifenberger G: **Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.** *Cancer Res* 1999, **59**:6091-6096.
137. MacPherson D, Dyer MA: **Retinoblastoma: from the two-hit hypothesis to targeted chemotherapy.** *Cancer Res* 2007, **67**:7547-7550.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

